<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03376646</url>
  </required_header>
  <id_info>
    <org_study_id>CL-VP-02</org_study_id>
    <nct_id>NCT03376646</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary Small Vessel Disease</brief_title>
  <official_title>A Multicenter, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of Dissolve™ Compared to Resolute™ Integrity in Treatment of Coronary Small Vessel Disease in Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DK Medical Technology (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Core Medical (Beijing) Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>DK Medical Technology (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety in the treatment of Coronary&#xD;
      Small Vessel Disease by drug coated balloon (DCB) Dissolve™ versus drug eluting stent (DES)&#xD;
      Resolute™ Integrity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 20, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Actual">January 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment percent diameter stenosis of the target lesion at 9 months after procedure</measure>
    <time_frame>9 months after the procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success rate of the interventional therapy</measure>
    <time_frame>From the start of index procedure to the end of index procedure, Day 0</time_frame>
    <description>Successful delivery and use of the assigned balloon/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final residual stenosis of less than 50% and TIMI 3 blood flow (DCB arm) or less than 30% and TIMI 3 blood flow (DES arm) by visual estimation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion success rate of the interventional therapy</measure>
    <time_frame>From the start of index procedure to the end of index procedure, Day 0</time_frame>
    <description>Attainment of final residual stenosis of less than 50% and TIMI 3 blood flow (DCB arm) or less than 30% and TIMI 3 blood flow (DES arm) by visual estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success rate of the interventional therapy</measure>
    <time_frame>7 days after the procedure</time_frame>
    <description>Without the occurrence of cardiac death, target vessel Myocardial Infarction (MI) or repeat target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-device percent diameter stenosis of the target lesion</measure>
    <time_frame>9 months after the procedure</time_frame>
    <description>Restenosis is defined as stenosis &gt; 50% by angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-device minimal lumen diameter (MLD)</measure>
    <time_frame>9 months after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment MLD</measure>
    <time_frame>9 months after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-device late lumen loss (LLL)</measure>
    <time_frame>9 months after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment LLL</measure>
    <time_frame>9 months after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis rate in lesion section</measure>
    <time_frame>9 months after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR) rate</measure>
    <time_frame>1 month, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years and 5 years after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure (TLF) rate</measure>
    <time_frame>1 month, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years and 5 years after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR) rate</measure>
    <time_frame>1 month, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years and 5 years after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all adverse events and severe adverse events</measure>
    <time_frame>1 month, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years and 5 years after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major adverse cardiovascular events</measure>
    <time_frame>1 month, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years and 5 years after the procedure</time_frame>
    <description>Including death, myocardial infarction (MI), stroke and renal failure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Coronary Small Vessel Disease</condition>
  <arm_group>
    <arm_group_label>Cohort A: Dissolve™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A: Resolute™ Integrity</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Dissolve™-2.00mm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B is single arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cohort A: Dissolve™</intervention_name>
    <description>Dissolve™ are to be used in the trial</description>
    <arm_group_label>Cohort A: Dissolve™</arm_group_label>
    <other_name>Paclitaxel coated balloon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cohort A: Resolute™ Integrity</intervention_name>
    <description>Resolute™ Integrity are to be used in the trial</description>
    <arm_group_label>Cohort A: Resolute™ Integrity</arm_group_label>
    <other_name>Zotarolimus eluting stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cohort B: Dissolve™-2.00mm</intervention_name>
    <description>Dissolve™ are to be used in the trial</description>
    <arm_group_label>Cohort B: Dissolve™-2.00mm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Related to the patients:&#xD;
&#xD;
        Cohort A:&#xD;
&#xD;
          1. Patients who agree to accept the angiography follow-up visit at 9-month and follow up&#xD;
             visits at 1-month, 6-month, 9-month, 1-year, 2-year, 3-year, 4-year and 5-year&#xD;
&#xD;
          2. Patients with stable angina, unstable angina, old myocardial infarction (including ST&#xD;
             elevation MI or Non-ST elevation MI) or proven asymptomatic ischemia&#xD;
&#xD;
          3. Patients who can receive any kind of coronary revascularization (including balloon&#xD;
             angioplasty, stent implantation or coronary artery bypass grafting)&#xD;
&#xD;
             Cohort B: All candidates for Cohort B of this study must meet number 1, 2 of the above&#xD;
             criteria and&#xD;
&#xD;
          4. Patients who can receive balloon angioplasty&#xD;
&#xD;
             Related to lesion:&#xD;
&#xD;
             Cohort A&#xD;
&#xD;
          5. The reference blood vessel diameter is 2.25 mm-2.75 mm, length ≤ 26mm&#xD;
&#xD;
          6. Before surgery, stenosis diameter must be ≥ 70% or ≥ 50% and accompanied by ischemia&#xD;
&#xD;
          7. One subject is allowed to have 1 target lesion at most (Two lesions can be treat as&#xD;
             one target lesion, if they are in the same vessel, with the distance less than 10mm,&#xD;
             with total length ≤ 26mm, and can be intervened by one DCB or DES)&#xD;
&#xD;
             Cohort B: All candidates for Cohort B of this study must meet number 6,7 of the above&#xD;
             criteria and&#xD;
&#xD;
          8. The reference blood vessel diameter is 2.00mm-2.25mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Related to patients&#xD;
&#xD;
          1. Patients who had Myocardial Infarction within 1 week before being included&#xD;
&#xD;
          2. Patients with severe congestive heart failure or NYHA grade IV heart failure&#xD;
&#xD;
          3. Left ventricular ejection fraction (LVEF) &lt; 35%&#xD;
&#xD;
          4. Patients who had heart transplantation&#xD;
&#xD;
          5. Patients with severe valvular heart disease&#xD;
&#xD;
          6. The patients had cerebral stroke within 6 months before being included, or have a&#xD;
             history of peptic ulcer or gastrointestinal bleeding, or the patients have a bleeding&#xD;
             tendency according to the investigator&#xD;
&#xD;
          7. Patients with leukopenia (white blood cell count &lt; 3×10^9/L) for more than three days;&#xD;
             Patients with low neutrophil counts (ANC &lt; 1000/mm^3) for more than three days;&#xD;
             Patients with thrombocytopenia (platelet count &lt; 100,000/mm^3)&#xD;
&#xD;
          8. Patients with renal insufficiency (eGFR &lt; 30mL/min)&#xD;
&#xD;
          9. Patients who are forbidden to use anticoagulation agents or anti-platelet drugs, and&#xD;
             unable to tolerate Aspirin or Clopidogrel&#xD;
&#xD;
         10. Patients who are allergic to Paclitaxel or Zotarolimus&#xD;
&#xD;
         11. The patients have a life expectancy of less than 12 months, or it would be difficult&#xD;
             to finish follow-ups within 12 months&#xD;
&#xD;
         12. Pregnant or lactating women, or women who plan to get pregnant within 12 months or&#xD;
             refuse to take effective contraceptives&#xD;
&#xD;
         13. The patients are participating in any other clinical trials before reaching the&#xD;
             primary endpoints&#xD;
&#xD;
         14. Patients who are unsuitable for the study according to the investigator due to other&#xD;
             reasons&#xD;
&#xD;
             Related to the Lesion:&#xD;
&#xD;
         15. Patients with total occlusion at the target lesion&#xD;
&#xD;
         16. Patients who have severe calcification of the target lesion, and balloon&#xD;
             pre-dilatation could not be performed successfully&#xD;
&#xD;
         17. The target lesions are bifurcation lesion with the diameter of the branch vessel &gt;&#xD;
             2.00mm&#xD;
&#xD;
         18. The target lesions are in-stent restenosis&#xD;
&#xD;
         19. Angiography indicates thrombosis in the target vessel&#xD;
&#xD;
         20. Complicated with lesions in left main (LM) coronary requiring intervention treatment&#xD;
&#xD;
         21. More than 2 non-target lesions need treatment, or the non-target lesion could not be&#xD;
             intervened successfully before the target lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shubin Qiao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Daqing Oil Field</name>
      <address>
        <city>Daqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University School of medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 8, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

